^
Association details:
Biomarker:No biomarker
Cancer:Nasopharyngeal Carcinoma
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
12/08/2021
Excerpt:
SYSTEMIC THERAPY FOR NASOPHARYNGEAL CANCERS: Other Recommended Regimens...Cisplatin/gemcitabine + PD-1 inhibitor (eg pembrolizumab or nivolumab)
Secondary therapy:
cisplatin + gemcitabine